ICM
ORCL icon

Invenomic Capital Management’s Oracle ORCL Stock Holding History

Invenomic Capital Management’s Portfolio ORCL Stock Details ORCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-243,303
Closed -$14.9M – 163
2022
Q3 		$14.9M Buy
+243,303
New +$17.8M 1.28% 25
2021
Q2 		– Sell
-17,845
Closed -$1.25M – 141
2021
Q1 		$1.25M Buy
+17,845
New +$1.16M 0.28% 67
2020
Q3 		– Sell
-17,270
Closed -$954K – 172
2020
Q2 		$954K Sell
17,270
-41,693
-71% -$2.21M 0.71% 49
2020
Q1 		$2.85M Buy
58,963
+549
+0.9% +$28.3K 2.33% 7
2019
Q4 		$3.1M Buy
+58,414
New +$3.22M 1.24% 31

Other funds holding ORCL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Invenomic Capital Management's ORCL Position: Q4 2022 in Review

Invenomic Capital Management sold out of Oracle (ORCL) in Q4 2022, closing a stake of 243,303 shares — an estimated $14.9M sold.

Invenomic Capital Management first reported a position in ORCL in Q4 2019 and held it in 5 quarters. The position peaked at $14.9M in Q3 2022. 2,299 funds tracked by Wall St. Rank hold ORCL as of Q4 2022.

  • Invenomic Capital Management reported no remaining Oracle position as of Q4 2022 after selling out during the quarter.
  • Invenomic Capital Management sold 243,303 Oracle shares in Q4 2022, an estimated $14.9M.
  • Invenomic Capital Management first reported a position in Oracle in Q4 2019 and held it in 5 quarters.
  • Invenomic Capital Management's Oracle position peaked at $14.9M in Q3 2022.
  • 2,299 funds tracked by Wall St. Rank held Oracle as of Q4 2022.

Based on Invenomic Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.